Invitation
Delayed Due to the COVID-19 Pandemic2022 SAPA-China (Chengdu) Annual Conferencewill be held onApril 06-07InChengdu, SichuanGrandly Convened. The conference will center on themes such as the ecosystem of China’s pharmaceutical and biotechnology development, strategies for drug innovation, and the most advanced international scientific technologies. It will feature a series of activities, including high-level forums, professional seminars, project matchmaking, financing promotions, and corporate exhibitions. The conference content covers the entire industry chain, from source innovation in the pharmaceutical sector to applied research, clinical development, commercialization, and investment and financing. This event is not only a rare international academic gathering but also an excellent platform for the integration of capital and projects.
SAPA is the most active and largest Chinese-majority professional organization in the biopharmaceutical sector in North America, with over 8,000 members worldwide. The association’s mission is to advance the development of biopharmaceutical science and technology, foster industrial investment and business collaboration, promote public health education, and support and facilitate the career development of its members.
SAPA is headquartered in the New Jersey–Greater New York area of the United States, with additional chapters in the New England region (Boston NE), the Greater Philadelphia region (Philadelphia GP), Washington, D.C. (DC), Connecticut (CT), the Midwest (Chicago MW), and China. SAPA members specialize in areas including target research and development for innovative drugs; preclinical and clinical developability studies; process development and manufacturing of small-molecule chemical drugs and large-molecule biologics; market access, registration, and regulatory submissions; commercialization, marketing, and sales; research and production technologies for improved new drugs; as well as investment, financing, and business collaboration.
Since its inception, SAPA has made significant contributions to advancing the biopharmaceutical industry, earning a strong reputation and widespread respect. For more information about SAPA, please visit www.sapaweb.org. The conference is expected to attract thousands of representatives from biopharmaceutical innovators, multinational pharmaceutical companies, and research institutions in China and the United States. We sincerely invite you to join this prestigious event and look forward to meeting you in Chengdu!
Dr. Hu Jiangbin, President of SAPA-China
Organizing Committee of the SAPA-China 2022 Annual Conference
Scan the QR Code to Register
Time:April 06–07, 2023
Location:InterContinental Chengdu Century City Paradise Hotel
(No. 88, Shijicheng Road, Wuhou District, Chengdu City, Sichuan Province)
04/06 Morning
[ Host ]
Dr. Hu Jiangbin, Dr. Liu Jian, and Dr. Xu Zhixin
◈ 08:30-09:00
Opening Remarks/Ceremony, Chengdu Hi-Tech Industrial Development Zone
◈ 09:00-09:30
Organocatalysis and Photoredox Asymmetric Organocatalysis and Photoredox Reactions
Prof. David MacMillan
2021 Nobel Prize in Chemistry Laureate
Professor at Princeton University
◈ 09:30-10:00
Advances in New Technologies for Vaccine Development
Academician Wei Yuquan
Academician of the Chinese Academy of Sciences
Director, State Key Laboratory of Biotherapy for Human Diseases, Sichuan University
◈ 10:00-10:30
Topic to be determined
Liu Gexin
Chairman of Sichuan Kelun Industrial Group
◈ 10:30-10:45
Tea Break Networking
◈ 10:45-11:15
Building a Drug Innovation Ecosystem under the New Development Paradigm
President Zhang Wei
President of the Chinese Society for Drug Regulatory Science
Former Secretary-General of the Chinese Pharmacopoeia Commission
◈ 11:15-11:45
Pyroptosis: Mechanism and Therapeutics Potential
Academician Shao Feng
Academician of the Chinese Academy of Sciences
◈ 11:45-12:15
Development of High-Quality Drugs Guided by Clinical Needs
Prof. Liu Jin
Professor, West China Hospital
Director, Department of Anesthesiology and Surgery, West China Hospital
◈ 12:15-13:00
Lunch Break
Slide to view the detailed agenda
04/06 PM
Bottlenecks in Small-Molecule Drug Development and Countermeasures
[ Host ]
Dr. Zhang Hancheng
◈ 13:00-13:30
Reflections on Project Initiation for the R&D of Innovative Small-Molecule Drugs
Dr. Tao Weikang
Vice President, Qilu Pharmaceutical Group / General Manager, Global Innovative R&D
◈ 13:30-14:00
Pharmaceutical Innovation and R&D in the Era of Hyper-Competition
Dr. Yunlong Song
General Manager of Shanghai Yishi Pharmaceutical, CSPC Pharmaceutical Group
◈ 14:00-14:30
Undruggable Targets and iADCs—New Opportunities in Oncology Therapy
Dr. Long Wei
Vice President, Preclinical R&D, Jacobio Pharmaceuticals
◈ 14:30-15:00
From Empirical Design to Rational Design
Dr. Wang Tielin
Senior Vice President of New Drug R&D, Yahong Medicine
◈ 15:00-15:20
Tea Break & Networking
◈ 15:20-15:50
Agenda TBD
Dr. Cui Jisong
Chairman of InnoCare Pharma
◈ 15:50-16:20
Pharmacodynamic Studies of Novel Molecular Entities
Dr. Xu Deming
Executive Director, WuXi AppTec Biology Division
◈ 16:20-17:00
Roundtable Discussion:
Bottlenecks in Small-Molecule Drug Development and Countermeasures
[ Host ]
Dr. Han Cheng Zhang
[ Guest ]
Dr. Liu Jian
Dr. Tao Weikang
Dr. Song Yunlong
Dr. Wang Tielin
Dr. Ji Song Cui
Dr. Xu Deming
Dr. Wang Xiaodong
04/07 AM
Differentiated Small-Molecule Innovative R&D Facilitates International Cooperation
[ Host ]
Dr. Haifeng Cui
◈ 08:30-09:05
AI and Robotics Laboratory Empowers New Drug R&D
Dr. Feng Ren
Insilico Medicine Co-CEO
◈ 09:05-09:40
Going Global: Differentiated Considerations and Case Studies of Jimin Kexin’s Innovative Small-Molecule Drugs
Dr. Jianbiao Peng
Dean, Jimin Kexin Institute for Small-Molecule Innovation
◈ 09:40-10:15
International Innovative Drug R&D from Another Perspective
Dr. Cai Jianhua
WuXi Biologics SVP
◈ 10:15-10:35
Tea Break Networking
◈ 10:35-11:10
R&D Progress and Potential Opportunities in Ion Channel Targets
Dr. Li Yingji
Founder/CEO of Beijing iSPEAK Biotechnology
◈ 11:10-11:45
AI-Empowered Integrated Platform for Small Molecule Drug Discovery
Dr. Hongbo Zhang
VP of Business Development, Beijing Wangshi Smart Technology
◈ 11:45-13:00
Lunch Break
04/07 PM
New Technology Platforms Drive BIC/FIC Drug Development
[ Host ]
Dr. Li Jian
◈ 13:00-13:30
Applications and Development Trends of DNA-Encoded Library Technology
Dr. Li Jin
Chairman/CEO of Chengdu HitGen
◈ 13:30-14:00
PROTAC Technology and the Development of Novel Antitumor Drugs
Dr. Chen Yuanwei
Chairman/CEO of Chengdu Haichuang Pharmaceutical Co., Ltd.
◈ 14:00-14:30
AI for Science: A New Paradigm Driving Drug Discovery for Challenging Targets
Dr. Zhang Xiaomin
Chief Pharmaceutical Officer at DP Technology
◈ 14:30-15:00
Current Status of Research and Development of Small-Molecule Immuno-Oncology Drugs
Dr. Zhang Xingmin
Chairman of Beijing Bohui Biology
◈ 15:00-15:20
Tea Break Networking
◈ 15:20-15:50
PDX Model Library for Clinical Trial Simulation
Dr. Chen Dawei
Co-Founder/Chief Scientific Officer, Chuangmo Bio
◈ 15:50-17:00
Roundtable Discussion:
New Technology Platforms Drive the R&D of BIC/FIC Drugs
[ Host ]
Dr. Li Jian
[ Guest ]
Dr. Li Jin
Dr. Yuanwei Chen
Dr. Zhang Xiaomin
Dr. Xingmin Zhang
Dr. Chen Dawei
Swipe to view the detailed agenda
04/06 PM
Antibody Drugs
[ Host ]
Dr. Xia Mingde
InnoLake Pharma Chairman/CEO
SAPA Director, Former President of the Headquarters
◈ 13:00-13:30
Development of Bispecific Antibody-Drug Conjugates Based on RenLite Mice with Shared Light Chain Fully Human Antibodies
Dr. Shen Yuelei
Chairman of Biocytogen
◈ 13:30-14:00
Agenda to be determined
Dr. Jingwu Zang
Founder/Chairman/Acting CEO of I-Mab
◈ 14:00-14:30
Innovative Drug Development in the Era of Tumor Immunotherapy 2.0
Dr. Hongtao Lu
Co-Founder/Director/Chief Scientific Officer of Kewang (Shanghai) Biopharmaceuticals
◈ 14:30-15:00
Challenges and Strategies in Antibody Discovery and Protein Expression/Purification During Early-Stage R&D
Dr. Wu Jiansheng
Vice President of WuXi Biologics, Head of the Cell and Protein Science Department
◈ 15:00-15:20
Tea Break & Networking
◈ 15:20-15:50
Fully Human Antibody Technology Platform Supports Global Biopharmaceutical Innovation
Dr. Rong Yiping
Senior Vice President/Head of Drug Discovery, Harbour BioMed
◈ 15:50-16:20
Selection of Animal Species for Nonclinical Safety Evaluation of Antibody Drugs
Cen Xiaobo
Director, National Chengdu Center for New Drug Safety Evaluation, West China Hospital of Sichuan University
General Manager of Chengdu Huaxi Haiqi Pharmaceutical Co., Ltd.
◈ 16:20-17:00
Roundtable Discussion:
How Antibody Drugs Can Go Global and Avoid Cutthroat Competition in the VUCA Era
[ Host ]
Dr. Xia Mingde
InnoLake Pharma Chairman/CEO
SAPA Director, Former President of the Headquarters
[ Guest ]
Dr. Tian Wenzhi
Dr. Shen Yuelei
Dr. Zang Jingwu
Dr. Hongtao Lu
Dr. Rong Yiping
04/07 AM
XDC Drugs
[ Host ]
Dr. Xia Mingde
Chairman/CEO of InnoLake Pharma
SAPA Director, Former President of the Headquarters
Gao Yu
◈ 08:30-09:00
Preclinical Studies of Next-Generation Antibody-Drug Conjugates (ADCs)
Dr. Baiteng Zhao
CEO of Pufang Biopharmaceuticals
◈ 09:00-09:30
Frontier Advances in ADC Drugs
Dr. Xiao Liang
Co-Founder of Suzhou Yilian Biopharma
◈ 09:30-10:00
Agenda to be determined
Dr. Huang Jinkun
CEO/Founder, Chengdu Xilingyuan
◈ 10:00-10:20
Tea Break & Networking
◈ 10:20-10:50
ADC Product Design and Development Strategies Centered on Biological Mechanisms
Chen Rulei
Co-Founder/Chief Operating Officer of InnoLake Pharma
◈ 10:50-11:20
XupremAbTM AI-Driven Next-Generation Antibody Discovery Technology Platform
Li Yi
Vice President of Strategic Development, XtalPi
Head of Antibody Business Line
◈ 11:20-12:00
Roundtable Discussion
[ Host ]
Gao Yu
[ Guest ]
Dr. Baiteng Zhao
Dr. Xiao Liang
Dr. Huang Jinkun
Chen Rulai
Li Yi
◈ 12:00-13:00
Lunch Break
04/07 PM
RNA Therapeutics
[ Host ]
Dr. Mingde Xia
Chairman/CEO of InnoLake Pharma
SAPA Director, Former Headquarters President
Dr. Yuan Jijun
◈ 13:00-13:30
Development and Prospects of Circular RNA Technology: From Basic Research to Drug Development
Dr. Yang Yun
Co-Founder/CTO of Huanma Biology
◈ 13:30-14:00
Clinical Studies of Tumor mRNA Vaccines in Glioblastoma
Professor Li Shiyu
Co-founder/CTO of Qichensheng
◈ 14:00-14:30
Advances and Prospects in Oligonucleotide Delivery
Shi Yibin
CEO of Darui Biotech
Eli Lilly Partner
◈ 14:30-15:00
Application of High-Efficiency mRNA Expression in Drug Development
Dr. He Li
Chief Operating Officer, Astecan
Former President of SAPA-NE
◈ 15:00-15:20
Tea Break & Networking
◈ 15:20-15:50
Core Raw Materials and Platform Technology Layout for mRNA Therapeutics
Dr. Xiao Xiao
Co-founder of Shenji Biotechnology
◈ 15:50-16:20
AI-Driven Nucleic Acid Drug Delivery and Drug Discovery
Dr. Wenshou Wang
Co-founder/Chief Operating Officer, Metagenomi
◈ 16:20-17:00
Roundtable Discussion:
Prospects and Greatest Challenges in Nucleic Acid Drug Development
[ Host ]
Dr. Yuan Jijun
[ Guest ]
Dr. Xin Dong
President Huang Zhen
Dr. Wang Wenshou
Slide to View Detailed Agenda
04/06 PM
Special Session on Innovative Vaccine Development
[ Host ]
Shi Nianmin, Chief Physician; Dr. Shi Li
◈ 13:00-13:30
Clinical Studies on Sequential Booster Vaccination for COVID-19 Vaccines
Professor Zhu Fengcai
Deputy Director of Jiangsu Provincial Center for Disease Control and Prevention
◈ 13:30-14:00
Preclinical Immunological Studies on Vaccines Against SARS-CoV-2 Variants
Professor Li Qihan
Tenured Professor, Peking Union Medical College
◈ 14:00-14:30
Clinical Study of Next-Generation COVID-19 Vaccines in Populations with Mixed Immune Backgrounds
Dr. Li Jingxin
Deputy Director, Institute for Clinical Evaluation of Vaccines, Jiangsu Provincial Center for Disease Control and Prevention
◈ 14:30-15:00
Research and Development Progress of Vaccines Against Hospital-Acquired Multidrug-Resistant Bacteria
Shi Nianmin, Chief Physician
President, Beijing Society of Biological Products
◈ 15:00-15:20
Tea Break Networking
◈ 15:20-15:50
Original Novel Drug 1.1: Progress in Phase II Clinical Trials of the Staphylococcus aureus Vaccine
Professor Zou Quanming
Army Medical University
Director, National Engineering Research Center for Immunological Biologics
◈ 15:50-16:20
Progress in the Development of Respiratory Syncytial Virus (RSV) Vaccines
Dr. Bin Wang
Professor at Fudan University
◈ 16:20-17:00
Roundtable Discussion:
Development of Contemporary Clinical Vaccine Research and Discussion of Related Issues
[ Host ]
Chief Physician Shi Nianmin
[ Guest ]
Professor Zhang Jun
Prof. Zhu Fengcai
Professor Li Qihan
Dr. Jingxin Li
Professor Zou Quanming
Dr. Wang Bin
April 7, Morning
Special Session 1: Training on Contemporary Vaccine Clinical Trials
[ Host ]
Chief Physician Shi Nianmin, Dr. Shi Li
◈ 08:30-09:00
mRNA Platform-Based Rabies Vaccine: Persistence of Immune Response and Challenge Protection
Professor Xu Jianqing
Professor at Fudan University
Founder of Xinwan Biotech
◈ 09:00-09:30
Quality Control in Clinical Trials of Vaccines
Mo Zhaojun
General Manager of Shanghai Standard
◈ 09:30-10:00
Implementation and Management of Vaccine Clinical Trials
Director Liu Xiaoqiang
Assistant to the Director, Yunnan Provincial Center for Disease Control and Prevention
Director of the Vaccine Clinical Research Center
◈ 10:00-10:20
Tea Break & Networking
◈ 10:20-10:50
Investigator Responsibilities in Vaccine Clinical Trials
Director Pu Hongxin
Director, Phase I Clinical Trial Research Office, Affiliated Hospital of Yanbian University
◈ 10:50-11:20
Lessons Learned from Overseas Clinical Trials of Vaccines
Deng Xiaoyu
Founder of Suzhou Xiyi Medicine
◈ 11:20-12:00
Roundtable Discussion:
Current Developments and Related Issues in Clinical Research on Vaccines
[ Host ]
Director Li Rongcheng
[ Guest ]
Director Yang Beifang
Liu Yan
Mo Zhaojun
Director Liu Xiaoqiang
Director Pu Hongxin
Deng Xiaoyu
◈ 12:00-13:00
Lunch Break
04/07 PM
Special Session 2 on Training for Contemporary Vaccine Clinical Trials
[ Host ]
Chief Physician Shi Nianmin, Dr. Shi Li
◈ 13:00-13:30
Surveillance of Suspected Adverse Events Following Immunization
Sun Meiping, Chief Physician
Chief Physician, Beijing Center for Disease Control and Prevention
◈ 13:30-14:00
Statistical Design and Evaluation of Vaccine Clinical Trials
Prof. Xia Jielai
Department of Statistics, Fourth Military Medical University
◈ 14:00-14:30
Quality Control in Multicenter Clinical Trials of Vaccines
Professor Li Yanping
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
◈ 14:30-15:00
Ethical Considerations in Vaccine Clinical Trials
Prof. Zhai Xiaomei
Professor at Peking Union Medical College
◈ 15:00-15:20
Tea Break Networking
◈ 15:20-15:50
Quality Control in Vaccine Clinical Trials
Chief Physician Hu Yuemei
Chief Physician, Jiangsu Provincial Center for Disease Control and Prevention
◈ 15:50-16:20
Quality Verification of Data Management in Vaccine Clinical Trials
Prof. Ruihua Sun
Professor at Beijing University of Chinese Medicine
◈ 16:20-17:00
Roundtable Discussion:
Current Developments in Clinical Vaccine Research and Discussion of Related Issues
[ Host ]
Dr. Shi Li
[ Guest ]
Sun Meiping, Chief Physician
Professor Xia Jielai
Prof. Li Yanping
Professor Zhai Xiaomei
Chief Physician Hu Yuemei
Prof. Sun Ruihua
Slide to view the detailed agenda
04/06 PM
New Technologies and Advances in Immune Cell Therapy
[ Host ]
Dr. Dai Weiguo
◈ 13:00-13:30
General Strategies and Clinical Exploration of Allogeneic CAR-T Cell Technology
Shang Xiaoyun
Founder/CEO of Suzhou Maohang Biotech
◈ 13:30-14:00
Challenges and Opportunities in the Development of iPSC-CAR-NK Cell Therapeutics
Dr. Dai Weiguo
Chairman/CEO of Monroe Bio
Former President of SAPA Headquarters
◈ 14:00-14:30
Research and Development Progress of TILs in Solid Tumors
Dr. Zhong Mengyang
Co-Founder of Gravel Bio
◈ 14:30-15:00
New Technologies in TCR-T Drug Development
Su Zhenbo
Chairman of Tiankeya Biotechnology
◈ 15:00-15:20
Tea Break & Networking
◈ 15:20-15:50
Next-Generation Red Blood Cell Immune Technology Platform for Cancer Therapy
Dr. Gao Xiaofei
Founder/Chairman of Westlake BioPharmaceutical
◈ 15:50-16:20
Analysis of Key Points and Strategies for Preclinical Evaluation of Immune Cell Therapy Products at the IND Stage from a Practical Perspective
Dr. Yang Cao
Director of the Pharmacology Department, Joinn (Suzhou) New Drug Research Center
Deputy General Manager, New Drug Research Execution, Joinn Laboratories (Suzhou) Co., Ltd.
◈ 16:20-17:00
Roundtable Discussion:
[ Host ]
Dr. Wei-Guo Dai
[ Guest ]
Dr. Zhong Mengyang
Su Zhenbo
Dr. Gao Xiaofei
Dr. Yang Cao
04/07 AM
New Technologies in Gene Therapy
[ Host ]
Dr. Wu Zhenhua
◈ 08:30-09:00
Agenda TBD
Dr. Haoquan Wu
Founder/CEO of Kanglin Biotech
◈ 09:00-09:30
Current Status and Challenges in the Development of Gene Therapy Drugs for Rare Diseases: From a Rush to Enter the Field to a Flourishing Landscape
Dr. Lin Qing
Founder/CEO of Lingyi Bio
◈ 09:30-10:00
The Past, Present, and Future of Gene Therapy
Dr. Wu Zhenhua
Founder/CEO of Hangzhou Jiayin Biologics
Former President of SAPA-GP
◈ 10:00-10:20
Tea Break Networking
◈ 10:20-10:50
General Considerations for Nonclinical Research and Evaluation of Gene Therapy Drugs
Dai Xuedong
Vice President, SaiFu Pharmaceutical Group
Pharmacology and Toxicology Expert
◈ 10:50-11:20
Topic TBD
Dr. Zhang Jiayi
Founder/CEO of Hangzhou Yunxin Zhili
◈ 11:20-12:00
Roundtable Discussion:
Challenges of Gene Therapy in the New Competitive Landscape
[ Host ]
Dr. Wu Zhenhua
[ Guest ]
Dr. Haoquan Wu
Dr. Lin Qing
Dai Xuedong
Dr. Zhang Jiayi
◈ 12:00-13:00
Lunch Break
04/07 PM
New Advances in the Clinical Development and Translation of Immunotherapy
[ Host ]
Dr. Dai Weiguo, Prof. Chen Bao'an
◈ 13:00-13:30
Bridging the “Valley of Death” in Translational Research of Cell Therapy for Solid Tumors: Ideals vs. Reality
Dr. Lu You
Deputy Director of the Cancer Center, West China Hospital, Sichuan University
Director, Thoracic Oncology Ward; Director, Clinical Cell Therapy Research Laboratory
◈ 13:30-14:00
Immune Cell Engineering Strategies Targeting the Characteristics of the Tumor Microenvironment
Dr. Zhang Yi
Director, Center for Biological Cell Therapy, The First Affiliated Hospital of Zhengzhou University
◈ 14:00-14:30
CAR-T Cell Therapy Strategies Based on Disease Characteristics
Professor Wang Yongsheng
West China Hospital Cancer Center
Deputy Director / Deputy Head of Clinical Research Department
Clinical Research on Innovative Drugs by the National Medical Products Administration and
Evaluation of the Director of the Key Laboratory
◈ 14:30-15:00
Clinical Trial Study on the Safe and Efficacious Treatment of Refractory/Recurrent Advanced Tumors (Including Solid Tumors) with Super Hi-TCR-T
Dr. Gao Jimin
Qianjiang Distinguished Professor at Wenzhou Medical University
◈ 15:00-15:20
Tea Break Networking
◈ 15:20-15:50
Gene Editing and Cell Therapy: From Basic Research to Clinical Translation
Dr. Liu Mingyao
Director, Institute of Life and Medical Sciences, East China Normal University
Founder/Chairman of Shanghai Bioray Laboratory
◈ 15:50-16:20
γδ T Cell Therapeutics and Platform Applications
Prof. Zhinan Yin
Dean, Institute of Biomedical Translation, Jinan University
◈ 16:20-17:00
Roundtable Discussion
[ Host ]
Professor Chen Bao'an
[ Guest ]
Dr. Lu You
Dr. Zhang Yi
Professor Wang Yongsheng
Dr. Gao Jimin
Dr. Mingyao Liu
Professor Yin Zhinan
Swipe to view the detailed agenda
June 4, PM
Quality Research on Drug Products and Active Pharmaceutical Ingredients
[ Host ]
Dr. Li Min
◈ 13:00-13:45
Challenges, Assessment, and Control Strategies for Nitrosamine Impurities
Dr. Li Min
Chief Scientist, Huahai Pharmaceutical
Chairman/General Manager of Shanghai Huahuituo Pharmaceutical Technology
Former President of SAPA Headquarters
◈ 13:45-14:15
Impurity Studies and Control Strategies
Professor Huo Xiumin
Former Senior Reviewer, Division I of Chemical Drugs, Center for Drug Evaluation (CDE)
◈ 14:15-14:45
A Novel Method for Genotoxicity Assessment of Nitrosamine Impurities Based on Cell-Based Sensors
Prof. Feng Zheng
Professor, Department of Pharmaceutical Analysis, China Pharmaceutical University
◈ 14:45-15:05
Tea Break Networking
◈ 15:05-15:35
High-Throughput Microreactors: Applications of Droplet Microfluidics in the Biopharmaceutical Field
Dr. Xu Xiaonan
Founder/Chairman of Dapu Biotech
◈ 15:35-16:20
Nonclinical Safety Evaluation of Drug Impurities
Dr. Wang Ying
Vice President of InnoCare Pharma
Former President and Chairman of SAPA Headquarters
◈ 16:20-17:00
Roundtable Discussion:
Quality Research on Drug Products and Active Pharmaceutical Ingredients
[ Host ]
Dr. Li Min
[ Guest ]
Prof. Huo Xiumin
Professor Zheng Feng
Dr. Xu Xiaonan
Dr. Ying Wang
April 07, Morning
CMC R&D, Process Development, Innovation, and Breakthroughs
[ Host ]
Dr. Zhiyun Wang, Dr. Junyou Ge
◈ 08:30-09:00
Development and Quality Control of ADC Drugs
Dr. Ge Junyou
Director, National Engineering Research Center for Biological Targeted Drugs
CEO of Kelun-Biotech
◈ 09:00-09:30
Strategic Considerations on the Translation of Basic Research into Applications for High-End Preparations in China
Professor Lu Weiyue
Professor at Fudan University
Founder of Taizhen Bio,
Chairman of the Pharmacy Professional Committee, Chinese Pharmaceutical Association
◈ 09:30-10:00
Continuous Manufacturing: Regulatory Requirements and Process Evaluation
Dr. Wang Zhiyun
Senior Vice President, Zai Lab
SAPA EC
SAPA China Executive Director
◈ 10:00-10:20
Tea Break & Networking
◈ 10:20-10:50
A Brief Analysis of Key CMC Considerations for mRNA Vaccines and Therapeutics
Dr. Park Hee-joon
Vice President, RNA Process, WuXi Biologics
◈ 10:50-11:20
Research on Lipid Carriers for Nucleic Acid Drugs Based on QbD
Dr. Xu Yuhong
CEO/Founder, Hangzhou Gaotian Biotechnology
◈ 11:20-12:00
Roundtable Discussion
Where Is the Next Frontier of Innovation for CMC?
[ Host ]
Dr. Wang Zhiyun
[ Guest ]
Dr. Tong Cai
Dr. Ge Junyou
Prof. Lu Weiyue
Dr. Park Hee-joon
Dr. Yuhong Xu
◈ 12:00-13:00
Lunch Break
04/07 PM
505(b)(2) Improved New Drugs in China and Abroad
[ Host ]
Dr. Wei Shifeng
◈ 13:00-13:30
Case Studies on Project Initiation and Development of Biological Drugs under the 505(b)(2) Pathway
Dr. Shi-Feng Wei
Chairman of Beijing Ronuoqiangshi Pharmaceutical Co., Ltd.
Former President of SAPA Headquarters
◈ 13:30-14:00
Research on Tumor Plastic Differentiation and Gene-Edited Biologics
Lv Wanliang
Tenured Professor at Peking University
Deputy Chair of the Pharmacy Professional Committee, Chinese Pharmaceutical Association,
Executive Director of the Chinese Society for Particuology
◈ 14:00-14:30
Research Progress and Strategies on Novel Drug Formulation Technologies
Prof. Wang Jianxin
Secretary of the Party Committee, Professor, School of Pharmacy, Fudan University
Member of the Pharmaceutical Professional Committee, Chinese Pharmaceutical Association,
Member of the Industrial Pharmacy Committee
◈ 14:30-15:00
Advantages and Challenges of Albumin Nanoparticle Formulations
Dr. Wang Baoli
Director of R&D Technology, Jianyou Biochemical Pharmaceutical
◈ 15:00-15:20
Tea Break Networking
◈ 15:20-15:50
Analysis of the Connotation of Clinical Advantages of Improved High-End Formulations
Professor Yang Jin
Professor at China Pharmaceutical University
◈ 15:50-16:20
Development of New Combination Drugs and Novel Dosage Forms in the Central Nervous System Field
Dr. Wang Peng
Co-founder/CSO of Ningdan New Drug
◈ 16:20-17:00
Roundtable Discussion:
Discussing Formulation Technology: Present and Future
[ Host ]
Dr. Wei Shifeng
[ Guest ]
Lu Wanliang
Prof. Wang Jianxin
Dr. Wang Baoli
Professor Yang Jin
Dr. Wang Peng
Slide to view the detailed agenda
04/06 PM
Pharmaceutical Companies’ Internationalization Strategy: International Drug Registration Regulations and Multicenter Clinical Trials
[ Host ]
Dr. Xu Zhixin, Dr. Wang Ying
◈ 13:00-13:35
Challenges and Strategies in the U.S. FDA Registration Process
Dr. Jinzhong Liu
FDA CDER OND Clinical
Data Science Staff Head
◈ 13:35-14:10
Clinical Value and the R&D of Original New Drugs
Dr. Xianping Lu
Chairman of Chipscreen Biosciences
◈ 14:10-14:45
Analysis and Reflections on the Marketing Authorization Applications for CAR-T Cell Therapy Products in China and the United States
Jia Xiuhong
Senior Director of Regulatory Affairs, Legend Biotech
◈ 14:45-15:05
Tea Break & Networking
◈ 15:05-15:40
Global Development Strategy for F-652, an Innovative Biologic Drug in Urgent Clinical Need
Dr. Jin Yuyan
Head of Clinical and Non-Clinical Operations, Shengyin Biologics,
Senior Vice President
◈ 15:40-16:15
Agenda to be determined
Inviting
◈ 16:15-17:00
Roundtable Discussion
How Enterprises Should Adjust Their Development Strategies in Light of Evolving International Relations
[ Moderator ]
Dr. Zhixin Xu
[ Guest ]
Dr. Lu Xianping
Jia Xiuhong
Dr. Jin Yuyan
04/07 AM
Globalization Strategies and Layout of Innovative Pharmaceutical Companies
[ Host ]
Dr. Lei Tang
◈ 08:30-08:55
Agenda to be determined
Dr. Xu Zengjun
Founder of Aistokang/
Chief Executive Officer
◈ 08:55-09:20
Strategic Considerations and Implementation Models for Product In-Licensing and Global Expansion by Chinese Pharmaceutical Companies
Dr. Shaoyu Chen
Managing Partner, King & Spalding LLP Shanghai Representative Office
◈ 09:20-09:45
Global MNCs’ Translational Medicine Strategy in China
Dr. Tang Lei
Head of Translational Medicine
and Early Development
Sanofi China
Former President of SAPA Headquarters
◈ 09:45-10:05
Tea Break Networking
◈ 10:05-10:30
Agenda to be determined
Inviting
◈ 10:30-10:55
Agenda TBD
Inviting
◈ 10:55-11:20
Strategies and Key Considerations for Innovative Drug Submissions in China, the United States, and Europe
Dr. Yuwen Hao
SVP, Global Regulatory Affairs, Andu Biopharma
◈ 11:20-12:00
Roundtable Discussion
Why Must Chinese Innovative Drugs Go Global Amid Adversity?
[ Host ]
Dr. Tang Lei
[ Guest ]
Dr. Xu Zengjun
Dr. Yuwen Hao
Dr. Shaoyu Chen
◈ 12:00-13:00
Lunch Break
04/07 PM
CDMO
[ Host ]
Dr. Wang Zhiyun, Dr. Ma Jianguo
◈ 13:00-13:30
Application of Green Technologies in Production
Dr. Jianguo Ma
CEO, Zhejiang Langhua Pharmaceutical
◈ 13:30-14:00
Requirements for the Clinical Section of an IND Application
Dr. Hao Li
CMO, Clinical Services, Pharmaron (Chengdu)
Founder of DetaiMai
◈ 14:00-14:30
Application of New Technologies and Novel Chemistry in Drug Process Development
Dr. Feng Shi
Deputy General Manager, Small Molecule Business Unit, Porton Pharma
◈ 14:30-15:00
"Strengthening R&D, Ensuring High-Standard Compliance, and Achieving Low-Cost Manufacturing"—Current Status and Future Plans of Apolo CDMO Business
Dr. Chongfeng Pan
Director, CDMO Manufacturing Center, Apeloa Pharmaceutical
◈ 15:00-15:20
Tea Break Networking
◈ 15:20-15:50
Topic TBD
Inviting
◈ 15:50-16:20
Agenda to be determined
Inviting
◈ 16:20-17:00
Roundtable Discussion
CDMO Sector Outlook and Strategic Direction
[ Host ]
Dr. Ma Jianguo
[ Guest ]
Dr. Li Hao
Dr. Feng Shi
Dr. Chongfeng Pan
Swipe to view the detailed agenda
04/06 PM
The Pros and Cons of Investment and Entrepreneurship
[ Host ]
Gao Yu, Yang Guangyao
◈ 13:00-13:30
Investment VS Entrepreneurship
Qiang Jing
Partner, Xingze Capital
Chairman/Founder of Xinnuowei
◈ 13:30-14:00
Focusing on R&D of Novel CNS Drugs to Meet the Growing Needs of Patients
Dr. Shen Huaqiong
Founder/CEO of NuOshen Pharma
◈ 14:00-14:30
Agenda to be determined
Fei Fan
EY Greater China
Co-Leading Partner, Life Sciences & Healthcare Industry
◈ 14:30-15:05
Roundtable Discussion
[ Host ]
Gao Yu
[ Guest ]
Shi Yibin
Dr. Guochun Li
Qiang Jing
Dr. Huaqiong Shen
Fei Fan
◈ 14:50-15:10
Tea Break & Networking
◈ 15:10-15:40
Agenda TBD
Dr. Xia Guoyao
Co-Founder/CEO of Libang Pharmaceutical
◈ 15:40-16:20
The Pros and Cons of Investment and Entrepreneurship
Dr. Zhongyuan Zhu
Founder/CEO of Duality Biologics
◈ 16:20-17:10
Roundtable Discussion
[ Host ]
Yang Guangyao
[ Guest ]
Dr. Li Chong
Attorney Ge Yongbin
Dr. Guo Yujie
Dr. Xia Guoyao
Dr. Zhongyuan Zhu
04/07 AM
Cross-border Licensing and Acquisitions: Building an Industry Ecosystem
[ Host ]
Dr. Shi Bin, Dr. Deng Lingquan
◈ 09:00-09:30
Topic to be determined
Harm-Jan Borgeld
Head of Asia Partnering, Roche Pharma Partnering (China)
◈ 09:30-10:00
Discussion on the Overseas Expansion Models of Innovative Pharmaceutical Companies
Qiu Xuan
Partner, Life Sciences Transaction Advisory, KPMG
◈ 10:00-10:20
Tea Break Networking
◈ 10:20-11:20
Roundtable Discussion
Innovation Going Global: International Pharmaceutical Regulations, Clinical Research, and Commercial Collaboration
[ Host ]
Dr. Bin Shi
[ Guest ]
Dr. Li Ning
Chen Chi
Li Kening
◈ 11:20-11:30
Roadshow 1
Professor Xu Jianqing
Professor at Fudan University
Founder of Xinwan Biotech
◈ 11:30-11:40
Roadshow 2
Dr. Zhang Hongjian
CEO of Weijiu Bio
◈ 11:40-11:50
Roadshow 3
◈ 11:50-12:00
Roadshow 4
◈ 12:00-13:00
Lunch Break
04/07 PM
Investor Forum
[ Host ]
Dr. Li Kechun, Dr. Dai Han
◈ 13:00-13:20
Primary Market Investment in Healthcare and Wellness: On the Path to the Exam
Dr. Li Jia
Partner, Lansheng Investment Group
◈ 13:20-13:40
Reflections on Primary Market Investment Amid the Pharmaceutical Winter
Chen Jie
Founding Partner, Yuan Sheng Ventures
◈ 13:40-14:00
Tax Strategies in Commercialization
Zhao Yimin
Deloitte’s Life Sciences & Health Care Industry Tax Advisory Leader Partner
◈ 14:00-14:10
Roadshow 1
◈ 14:10-14:20
Roadshow 2
◈ 14:20-14:30
Roadshow 3
◈ 14:30-14:40
Intranasally Administered Protein Mucosal Vaccines
Yan Huimin
Alloson Biotechnology (Suzhou) Co., Ltd.
◈ 14:40-14:50
Roadshow 5
◈ 14:50-15:10
Tea Break Networking
◈ 15:10-16:00
Roundtable Topic
[ Host ]
Li Kechun
[ Guest ]
Yan Shixiang
Huang Xin
Wang Yunhai
Liu Xin
Yu Zhiyun
◈ 16:00-16:50
Roundtable Topic
Reflections on the Internationalization and Global Expansion of China’s Biopharmaceutical Industry
[ Host ]
Dr. Han Dai
[ Guest ]
Yuan Jianwei
Zhou Naijun
Gao Jieliang
Chen Gang
He Xing
Yin Jie
Scan the QR Code to Register
Contact Us
| Business Cooperation
Mr. Jin
E: jinweijie@shengjiejituan.cn
| Conference Inquiry
Mr. Xie
E: xiewenbo@shengjiejituan.cn
| Media Partnership
Ms. Ma
E: majin@shengjiejituan.cn
Special Events
Alumni Association of the School of Pharmacy, Fudan Universityand
Alumni Networking Event of the Pharmacy Branch, Shanghai Medical University Alumni Association
★ Reunite with Alumni, Discuss Growth Together
Dear Alumni,The School of Pharmacy Alumni Association of Fudan University and the Pharmaceutical Branch of the Shanghai Medical University Alumni Association look forward to connecting with you to reminisce about our youth and reignite our dreams!
Scan the QR code below to register
Transportation Guide
[Conference Venue]
InterContinental Chengdu Century City(No. 88, Shijicheng Road, Wuhou District, Chengdu City, Sichuan Province)
【Transportation Information】
High-Speed Rail
Chengdu South Railway Station: 5.4 km, approximately by taxi to the venue13min
Chengdu East Railway Station: 15 km; taxi ride to the conference venue takes approximately21min
Chengdu Station: 22 km, approximately by taxi to the conference venue34min
Airplane
Chengdu Shuangliu International Airport: 21 km, approximately by taxi to the conference venue32min
Chengdu Tianfu International Airport: 58 km; approximately by taxi to the conference venue46min